No pharmacokinetic or pharmacodynamic interaction between theophylline and the leukotriene biosynthesis inhibitor BAY x 1005

Journal of Clinical Pharmacology

Volumn 36, Issue 7, 1996, Pages 639-646

  Groen, Henk ^a   Moesker, Harm L ^b   Leeuwenkamp, Oscar R ^a   Sollie, Frans A E ^a   Jonkman, Jan H G ^a  

^a PRA International USA   (Netherlands)

^b Bayer BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; THEOPHYLLINE;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; BRONCHUS REACTIVITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0029762221     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04229.x     Document Type: Article

References (17)

1. Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R: Mode of action of the new selective leukotriene synthesis inhibitor BAY x 1005 {(R)-2-[4-quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid} and structurally related compounds. Biochem Pharmacol 1993;45:101-111.
2. Müller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtmann R, Perzborn E, Beckermann B, et al: BAY x 1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Thor 1993;267: 51-57.
3. Fruchtmann R, Mohrs KH, Hatzelmann A, Raddatz S, Fugmann B, Junge B, et al: In vitro pharmacology of BAY x 1005, a new inhibitor of leukotriene synthesis. Agents Actions 1993;38:188-195.
4. Lewis RA, Austen KF, Soberman RJ: Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323: 645-655.
5. Samuelsson B: Arachidonic acid metabolism: role in inflammation. Z Rheumatol 1991;50:3-6.
6. Henderson WR Jr: Role of inflammation in asthma. Ann Allergy 1994;72:272-278.
7. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90:193-201.
8. Gorenne I, Labat C, Gascard JP, Morel X, Müller-Peddinghaus R, Mohrs KH, et al: (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x 1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther 1994;268:868-872.
9. Jonkman JHG, Upton RA: Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 1984;9:309-334.
10. Upton RA: Pharmacokinetic interactions between theophylline and other medication, parts I and II. Clin Pharmacokinet 1991;20:66-80, 135-150.
11. Jonkman JHG, Schoenmaker R, Greving JE, de Zeeuw RA: Rapid and selective theophylline serum and saliva assay by means of high pressure liquid chromatography. Pharm Weekbl Sci Ed 1980;2:49-53.
12. Shuirmann DJ: A comparison of the two-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-680.
13. 14C arachidonic acid labelled human lung tissue by high-performance liquid chromatography and radioimmunoassay. J Chromatogr 1984;311:39-50.
14. Mózes T, Zijlstra FJ, Heiligers JPC, Tak CJAM, Ben-Efraim S, Bonta IL, Saxena PR: Sequential release of tumour necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anaesthetized pigs: protective effect of indomethacin. Br J Pharmacol 1991;104:691-699.
15. Billing B, Dahlqvist R, Garle M, Hörnblad V, Ripe E: Separate and combined use of terbutaline and theophylline in asthmatics. Eur J Respir Dis 1982;63:399-409.
16. 2-adrenostimulants in asthmatics. Allergy 1982;37: 119-127.
17. 4 in asthmatic patients. Int J Tissue React 1993;15:101-104.